[Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001923:Brain Chemistry; D002319:Cardiovascular System / Q000187:drug effects; D002415:Cats; D004064:Digestive System / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004285:Dogs; D004298:Dopamine / Q000096:biosynthesis / Q000378:metabolism; D004357:Drug Synergism; D005116:Extrapyramidal Tracts / Q000378:metabolism; D005298:Fertility / Q000187:drug effects; D005333:Fetus / Q000187:drug effects; D006801:Humans; D051379:Mice; D009638:Norepinephrine / Q000032:analysis; D010300:Parkinson Disease / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D013268:Stimulation, Chemical
D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine
Die biochemischen Grundlagen für die Behandlung des Parkinson-Syndroms mit L-Dopa.